Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact?

A.N. Vis, T.M. van der Sluis, H.H.M. Al-Itejawi, R.J.A. van Moorselaar, E.J.H. Meuleman

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)7-15
JournalUrologic Oncology
Volume33
Issue number1
DOIs
Publication statusPublished - 2015

Cite this